Evidence map›Paper›PMID 42243893›Full record

ReviewJournal of nanobiotechnology2026

Iron-based magnetic nanoplatforms for immune microenvironment remodeling and cancer immunotherapy: progress and prospects.

Le Chang, Yiqi Yan, Cuixiang Xu, Jianhua Wang

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Le Chang *Shaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People's Hospital, Xi'an, 710068, China.
Yiqi Yan *Department of Graduate School, Yan'an University, Yan'an, 716000, China.
Cuixiang XuShaanxi Provincial Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People's Hospital, Xi'an, 710068, China. xucuixiang@spph-sx.ac.cn.
Jianhua WangSecond Department of General Surgery, Shaanxi Provincial People's Hospital, Xi'an, 710068, China. wangjianhuaman@163.com.

Funding

China Postdoctoral Science Foundation 2025M772875National Natural Science Foundation of China 12302411Shaanxi Province High-level Talent Cultivation Program, Shaanxi Provincial Health and Medical Research Innovation Capacity Enhancement Plan 2025YF-32,2024PT-01Shaanxi Province Innovation Capability Support Plan 2025ZC-KJXX-87,2024RS-CXTD-84Shaanxi Province Postdoctoral Research Program 2024BSHSDZZ039the Wu JiePing Medical Foundation 320.6750.2023-06-24Xi'an Municipal Science and Technology Bureau General Program of Medical Research 25YXYJYB00009
6 · The paper itself

Abstract

Cancer continues to be one of the leading causes of death worldwide. Although immunotherapy has transformed oncologic treatment by mobilizing the host immune system, the immunosuppressive tumor immune microenvironment (TIME) still constitutes a major barrier to durable clinical responses. Recent studies indicate that iron-based magnetic nanoparticles (Fe-MNPs) offer capabilities that extend beyond those of conventional drug delivery systems, acting instead as active regulators of the TIME. In this review, we outline current progress in Fe-MNP-mediated cancer immunotherapy and propose a conceptual framework to clarify their immunomodulatory effects. Specifically, Fe-MNPs can generate multiple physicochemical stimuli under magnetic field control, including magnetic hyperthermia, magnetically induced mechanical perturbation, and Fenton reaction-mediated oxidative stress. These upstream events converge to induce immunogenic stress, including ferroptosis-associated injury, which in turn promotes hypoxia alleviation, tumor-associated macrophage (TAM) reprogramming, dendritic cell activation, and enhanced effector T-cell responses. Together, these findings support a framework in which Fe-MNP-mediated immunomodulation is understood as an integrated cascade rather than a collection of isolated effects. However, challenges remain regarding biosafety, long-term iron metabolism, delivery efficiency, and large-scale manufacturing. Overall, this review provides a systematic overview of Fe-MNP-mediated immunomodulation and discusses the translational prospects of these materials as multifunctional platforms for cancer immunotherapy.

Indexed as

ImmunotherapyIronMagnetite NanoparticlesNeoplasmsTumor MicroenvironmentAnimalsHumansIronMagnetite NanoparticlesEffector T cellsFerroptosisImmunosuppressionIron-based magnetic nanoparticlesTumor-associated macrophagesTumor immune microenvironment

Identifiers

PMID42243893
PMCPMC13435462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.